2-HYDROXYPROPYL BETA-CYCLODEXTRIN (DS 4.2)
Niemann-Pick Disease, Type C1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)mixturePhase 1/2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 36/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Niemann-Pick Disease, Type C1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hydroxypropyl-Beta-Cyclodextrin Cyclo Therapeutics, Inc. | Phase 3 | BB |
Vorinostat Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1/2 | CCC |
LITHIUM, ELEMENTAL Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Early Phase 1 | C |
Same molecule, other indications
2-HYDROXYPROPYL BETA-CYCLODEXTRIN (DS 4.2) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →